Gazette.govt.nzPursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Product: | Nozinan |
| Active Ingredient: | Levomepromazine maleate 33.8mg equivalent to levomepromazine 25mg |
| Dosage Form: | Tablet |
| New Zealand Sponsor: | Sanofi-Aventis New Zealand Limited |
| Manufacturer: | Sanofi SpA, Scoppito, Italy |
|
Note: This consent is given subject to the following conditions: - Provisional consent is to be granted for 2 years to address an urgent shortage in the market. |
|
| Note: This consent is valid for two years from the date of publication of this notice. | |
| Product: | Nozinan |
| Active Ingredient: | Levomepromazine maleate 135mg equivalent to levomepromazine 100mg |
| Dosage Form: | Tablet |
| New Zealand Sponsor: | Sanofi-Aventis New Zealand Limited |
| Manufacturer: | Sanofi SpA, Scoppito, Italy |
|
Note: This consent is given subject to the following conditions: - Provisional consent is to be granted for 2 years to address an urgent shortage in the market. |
|
| Note: This consent is valid for two years from the date of publication of this notice. | |
Dated this 14th day of February 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).